Efficacy News and Research

RSS

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

26 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

OneWest Foundation, UCLA Health System grant $600,000 for helping low-income patients obtain medical care

Thanks to a generous three-year, $300,000 grant from the OneWest Foundation — matched by funds from the UCLA Health System — qualified Venice Family Clinic patients who need hospitalization or specialized medical care may now be helped by a pilot project launched by the foundation, the clinic and the UCLA Health System.

26 Feb 2010

STD prevention programs in schools: Mixed outcomes on sexual behaviors

Teaching teens about sexually transmitted infections at school boosts factual knowledge, but does not necessarily translate to increased condom use, according to a new review from the United Kingdom.

26 Feb 2010

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

26 Feb 2010

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

EKOS Corporation announced today that Dr. David W. Newell, Co–Executive Director, Swedish Neuroscience Institute (Seattle, WA) presented a SNI clinical study known as ‘SLEUTH’ (Safety of Lysis with Ultrasound in the Treatment of Intracerebral (ICH) and Intraventricular Hemorrhage (IVH) at the American Heart Association International Stroke Conference (San Antonio, TX).

26 Feb 2010

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.

26 Feb 2010

NORD lauds FDA's establishment of new position within CDER

Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), today said the Food and Drug Administration's (FDA) announcement that it has created a new position—Associate Director for Rare Diseases—in the agency's Center for Drug Evaluation and Research's (CDER) Office of New Drugs (OND) represents an important advance for patients with rare diseases.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to 4,000 people, or 1.5 million people worldwide.

25 Feb 2010

Orexo partner submits NDA for cancer pain drug Abstral in Japan

Orexo AB today announces that its partner Kyowa Hakko Kirin Co., Ltd. has submitted the New Drug Application (NDA) in Japan for the cancer pain drug KW-2246 (Abstral).

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

New data shows Valortim antibody enhances human T cell response to B. anthracis

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new data from the Company's Valortim® anthrax anti-toxin program were presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Maryland, February 21-24, 2010.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

FDA, NIH initiative: From scientific breakthrough to the availability of new medical therapies for patients

The U.S. Food and Drug Administration and the National Institutes of Health today unveiled an initiative designed to accelerate the process from scientific breakthrough to the availability of new, innovative medical therapies for patients.

25 Feb 2010

Efficacy News and Research

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Vion Pharmaceuticals' Onrigin SPA: FDA responds

OneWest Foundation, UCLA Health System grant $600,000 for helping low-income patients obtain medical care

STD prevention programs in schools: Mixed outcomes on sexual behaviors

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

SNI clinical study using ultrasound for treatment of ICH and IVH presented at International Stroke Conference

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

NORD lauds FDA's establishment of new position within CDER

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

Genta initiates new dose-ranging study of tesetaxel drug

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Study demonstrates Prochymal treamtent is safe for cardiac patients

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

Orexo partner submits NDA for cancer pain drug Abstral in Japan

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

New data shows Valortim antibody enhances human T cell response to B. anthracis

EpiCept provides business update and fourth-quarter financial highlights

FDA, NIH initiative: From scientific breakthrough to the availability of new medical therapies for patients

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News